A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

MLA

Chari, Ajai, et al. “A Phase 2 Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma.” Blood Advances, vol. 1, no. 19, Aug. 2017, pp. 1575–83. EBSCOhost, https://doi.org/10.1182/bloodadvances.2017007427.

APA

Chari, A., Cho, H. J., Dhadwal, A., Morgan, G., La, L., Zarychta, K., Catamero, D., Florendo, E., Stevens, N., Verina, D., Chan, E., Leshchenko, V., Laganà, A., Perumal, D., Mei, A. H.-C., Tung, K., Fukui, J., Jagannath, S., & Parekh, S. (2017). A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Advances, 1(19), 1575–1583. https://doi.org/10.1182/bloodadvances.2017007427

Chicago

Chari, Ajai, Hearn J Cho, Amishi Dhadwal, Gillian Morgan, Lisa La, Katarzyna Zarychta, Donna Catamero, et al. 2017. “A Phase 2 Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma.” Blood Advances 1 (19): 1575–83. doi:10.1182/bloodadvances.2017007427.